NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
Clinical Trials
11 trialsNCT03363373 2026-02-19
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
Phase 2 Recruiting
NCT06233903 2025-01-21
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2 Withdrawn
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT02998983 2023-09-11
Racotumomab in Patients With High-risk Neuroblastoma
Laboratorio Elea Phoenix S.A.
Phase 2 Completed
NCT03561259 2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2 Unknown
NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT00659984 2017-10-04
N2007-01: Ultratraceā¢ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Completed
NCT00992173 2015-11-26
Efficacy and Safety of Ultratraceā¢ Iobenguane I 131 in Neuroblastoma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00969722 2013-03-08
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
United Therapeutics
Phase 2 Terminated
NCT00520936 2011-02-25
A Study of Pemetrexed in Children With Recurrent Cancer
Eli Lilly and Company
Phase 2 Completed